首页> 外文期刊>Breast Cancer Research and Treatment >Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer
【24h】

Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer

机译:增殖标志物细胞周期蛋白A,组织学等级和雌激素受体状态的组合,对乳腺癌具有高预后影响的新变量

获取原文
获取外文期刊封面目录资料

摘要

Global gene expression profiles, consisting mainly of genes associated with proliferation, have been shown to subdivide histological grade 2 breast cancers into groups with different prognosis. We raised the question whether this subdivision could be done using a single proliferation marker, cyclin A. Furthermore, we combined cyclin A (CA), histological grade (G), and estrogen receptor—ER (E) into a new variable, CAGE. Our aim was to investigate not only the prognostic importance of cyclin A alone but also the value of the combination variable CAGE. In 219 premenopausal node-negative patients, cyclin A was assessed using immunohistochemistry on tissue microarrays. High cyclin A was defined as above the seventh decile of positive cells. Only 13% of the patients received adjuvant systemic therapy. Cox proportional hazards regression was used to model the impact of the factors on distant disease-free survival (DDFS). Cyclin A divided histological grade 2 tumors into two groups with significantly different DDFS (hazard ratio [HR]: 15, P < 0.001). When stratifying for ER status, cyclin A was a prognostic factor only in the ER positive subgroup. We found that CAGE was an independent prognostic factor for DDFS in multivariate analysis (HR: 4.1, P = 0.002), together with HER2. CAGE and HER2 identified 53% as low-risk patients with a 5-year DDFS of 95%. A new prognostic variable was created by combining cyclin A, histological grade, and ER (CAGE). CAGE together with HER2 identified a large low-risk group for whom adjuvant chemotherapy will have limited efficacy and may be avoided.
机译:已显示主要由与增殖相关的基因组成的全局基因表达谱将组织学2级乳腺癌细分为具有不同预后的组。我们提出了一个问题,是否可以使用单个增殖标志物细胞周期蛋白A来完成该细分。此外,我们将细胞周期蛋白A(CA),组织学等级(G)和雌激素受体(ER)合并为一个新变量CAGE。我们的目的不仅是研究细胞周期蛋白A的预后重要性,还研究组合变量CAGE的价值。在219名绝经前淋巴结阴性的患者中,在组织芯片上使用免疫组织化学评估了细胞周期蛋白A。高细胞周期蛋白A定义为高于阳性细胞的十分位数。只有13%的患者接受了辅助全身治疗。使用Cox比例风险回归对因素对遥远无病生存期(DDFS)的影响进行建模。细胞周期蛋白A将组织学2级肿瘤分为DDFS明显不同的两组(危险比[HR]:15,P <0.001)。在对ER状态进行分层时,细胞周期蛋白A仅在ER阳性亚组中是预后因素。我们发现在多变量分析中,CAGE是DDFS的独立预后因素(HR:4.1,P = 0.002)以及HER2。 CAGE和HER2确定53%为低危患者,其5年DDFS为95%。通过结合细胞周期蛋白A,组织学等级和ER(CAGE)创建了一个新的预后变量。 CAGE与HER2一起确定了一个大的低风险人群,对于其而言,辅助化疗的疗效有限,可以避免。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号